Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aclaris Therapeutics (ACRS) Other Operating Expenses: 2017-2025

Historic Other Operating Expenses for Aclaris Therapeutics (ACRS) over the last 9 years, with Sep 2025 value amounting to $2.5 million.

  • Aclaris Therapeutics' Other Operating Expenses fell 20.54% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $102.6 million, marking a year-over-year increase of 3222.98%. This contributed to the annual value of $104.9 million for FY2024, which is 4888.26% up from last year.
  • According to the latest figures from Q3 2025, Aclaris Therapeutics' Other Operating Expenses is $2.5 million, which was down 23.91% from $3.4 million recorded in Q2 2025.
  • In the past 5 years, Aclaris Therapeutics' Other Operating Expenses ranged from a high of $94.9 million in Q4 2024 and a low of -$13.2 million during Q4 2023.
  • For the 3-year period, Aclaris Therapeutics' Other Operating Expenses averaged around $10.0 million, with its median value being $2.5 million (2025).
  • Examining YoY changes over the last 5 years, Aclaris Therapeutics' Other Operating Expenses showed a top increase of 2,475.56% in 2023 and a maximum decrease of 253.74% in 2023.
  • Over the past 5 years, Aclaris Therapeutics' Other Operating Expenses (Quarterly) stood at $3.3 million in 2021, then surged by 157.21% to $8.6 million in 2022, then tumbled by 253.74% to -$13.2 million in 2023, then soared by 816.65% to $94.9 million in 2024, then declined by 20.54% to $2.5 million in 2025.
  • Its last three reported values are $2.5 million in Q3 2025, $3.4 million for Q2 2025, and $1.8 million during Q1 2025.